Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05001945 · ClinicalTrials.gov registry record · Phase 2
Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
A Phase 2 study, sponsored by Mineralys Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT05001945 is a Phase 2 study that has completed, run by Mineralys Therapeutics. The registered enrollment target is 200 participants.
The verdict
NCT05001945, a Phase 2 study, has completed, sponsored by Mineralys Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension
Interventions
- DRUG MLS-101 (Part I)
- OTHER Placebo (Part I)
- OTHER Placebo (Part II)
- DRUG MLS-101 (Part II)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2022-10-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05001945
The ClinicalTrials.gov registry entry for NCT05001945 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mineralys Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MLS-101 (Part I) is the first listed.
NCT05001945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05001945 about?
NCT05001945 is a clinical study titled "Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension". A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension
What is the current status of trial NCT05001945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2021-07-01. Estimated completion is 2022-10-07.
What interventions are being tested in trial NCT05001945?
The interventions under investigation include: MLS-101 (Part I) (DRUG), Placebo (Part I) (OTHER), Placebo (Part II) (OTHER), MLS-101 (Part II) (DRUG).
Who is sponsoring clinical trial NCT05001945?
This trial is sponsored by Mineralys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.